Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy


Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that data from the Phase 1 MoveDMD clinical trial of edasalonexent were published in the Journal of Neuromuscular Diseases, “Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-kB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy”. Edasalonexent was well tolerated in pediatric patients and the data demonstrated that edasalonexent inhibited NF-kB in pediatric patients with Duchenne muscular dystrophy (DMD). NF-kB is a key link between loss of dystrophin and disease progression in DMD. MoveDMD is a multi-part trial including Phase 1, Phase 2 and an on-going open-label extension. Catabasis is currently enrolling the Phase 3 PolarisDMD trial for edasalonexent.

https://www.duchennexchange.org/wp-content/uploads/2018/10/Catabasis-logo_RGB-high-res_9-2016.jpg